Olga Martelli

2.4k total citations · 1 hit paper
34 papers, 1.3k citations indexed

About

Olga Martelli is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Olga Martelli has authored 34 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Oncology, 18 papers in Pulmonary and Respiratory Medicine and 4 papers in Molecular Biology. Recurrent topics in Olga Martelli's work include Lung Cancer Treatments and Mutations (17 papers), Lung Cancer Research Studies (15 papers) and Lung Cancer Diagnosis and Treatment (10 papers). Olga Martelli is often cited by papers focused on Lung Cancer Treatments and Mutations (17 papers), Lung Cancer Research Studies (15 papers) and Lung Cancer Diagnosis and Treatment (10 papers). Olga Martelli collaborates with scholars based in Italy, United States and Lebanon. Olga Martelli's co-authors include Massimo Di Maïo, Cesare Gridelli, Antônio Rossi, Marina Chiara Garassino, Roberto Labianca, Gabriella Farina, Filippo de Marinis, Ciro Gallo, Calogero Lauricella and Massimo Broggini and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and Scientific Reports.

In The Last Decade

Olga Martelli

33 papers receiving 1.3k citations

Hit Papers

Erlotinib versus docetaxel as second-line treatment of pa... 2013 2026 2017 2021 2013 100 200 300
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial
    2013 376 citations Marina Chiara Garassino, Olga Martelli et al. The Lancet Oncology profile →

Peers

Olga Martelli
Libor Havel Czechia
J Thiriaux Belgium
Naruo Yoshimura Japan
Jessica Read United Kingdom
Maria Q. Baggstrom United States
Akihiro Nishiyama Japan
C. Manegold Germany
Jean-Louis Pujol France
Jiichiro Sasaki Japan
Gonçalo Forjaz United States
Libor Havel Czechia
Olga Martelli
Citations per year, relative to Olga Martelli Olga Martelli (= 1×) peers Libor Havel

Countries citing papers authored by Olga Martelli

Since Specialization
Citations

This map shows the geographic impact of Olga Martelli's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Olga Martelli with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Olga Martelli more than expected).

Fields of papers citing papers by Olga Martelli

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Olga Martelli. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Olga Martelli. The network helps show where Olga Martelli may publish in the future.

Co-authorship network of co-authors of Olga Martelli

This figure shows the co-authorship network connecting the top 25 collaborators of Olga Martelli. A scholar is included among the top collaborators of Olga Martelli based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Olga Martelli. Olga Martelli is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Minuti, Gabriele, Silvia Carpano, Ettore D’Argento, et al.. (2021). [Management of small cell lung cancer patient in the regions of Lazio, Umbria and Sardinia.]. PubMed. 112(10). 639–646. 1 indexed citations
2.
Nelli, Fabrizio, Agnese Fabbri, Luca Moscetti, et al.. (2020). Long-term outcome of pemetrexed maintenance for advanced nonsquamous non-small-cell lung cancer: a real-world observational cohort study. Recenti Progressi in Medicina. 111(12). 761–768. 2 indexed citations
3.
Celio, Luigi, Diego Cortinovis, Luigi Cavanna, et al.. (2020). 1815MO Two simplified dexamethasone (DEX)-sparing regimens with NEPA for the prevention of emesis caused by cisplatin (DDP): A phase III, controlled, non-inferiority trial. Annals of Oncology. 31. S1048–S1048. 1 indexed citations
4.
Capelletto, Enrica, Simona Carnio, Cesare Gridelli, et al.. (2016). Patients' Attitudes and Physicians' Perceptions Toward Maintenance Therapy for Advanced Non–Small-cell Lung Cancer: A Multicenter Italian Survey. Clinical Lung Cancer. 18(4). 381–387. 6 indexed citations
5.
Ganzinelli, Monica, Eliana Rulli, Elisa Caiola, et al.. (2015). Role of KRAS-LCS6 polymorphism in advanced NSCLC patients treated with erlotinib or docetaxel in second line treatment (TAILOR). Scientific Reports. 5(1). 16331–16331. 11 indexed citations
6.
Rulli, Eliana, Mirko Marabese, Valter Torri, et al.. (2015). Value of KRAS as prognostic or predictive marker in NSCLC: results from the TAILOR trial. Annals of Oncology. 26(10). 2079–2084. 40 indexed citations
7.
Verde, Nicla La, Elena Collovà, Sara Lonardi, et al.. (2013). Male breast cancer: Clinical features and multimodal treatment in a retrospective survey analysis at Italian centers. ArTS Archivio della ricerca di Trieste (University of Trieste https://www.units.it/). 3 indexed citations
8.
Verde, Nicla La, Elena Collovà, Sara Lonardi, et al.. (2013). Male Breast Cancer: Clinical Features and Multimodal Treatment in a Retrospective Survey Analysis at Italian Centers. Tumori Journal. 99(5). 596–600. 4 indexed citations
9.
Garassino, Marina Chiara, Olga Martelli, Massimo Broggini, et al.. (2013). Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial. The Lancet Oncology. 14(10). 981–988. 376 indexed citations breakdown →
10.
Rossi, Antônio, Olga Martelli, & Massimo Di Maïo. (2012). Treatment of patients with small-cell lung cancer: From meta-analyses to clinical practice. Cancer Treatment Reviews. 39(5). 498–506. 37 indexed citations
11.
Rossi, Antônio, Massimo Di Maïo, Paolo Chiodini, et al.. (2012). Carboplatin- or Cisplatin-Based Chemotherapy in First-Line Treatment of Small-Cell Lung Cancer: The COCIS Meta-Analysis of Individual Patient Data. Journal of Clinical Oncology. 30(14). 1692–1698. 381 indexed citations
12.
13.
Novello, Silvia, Michèle Milella, Marcello Tiseo, et al.. (2011). Maintenance therapy in NSCLC: why? To whom? Which agent?. Journal of Experimental & Clinical Cancer Research. 30(1). 50–50. 22 indexed citations
14.
Roila, Fausto, Enzo Ballatori, Roberto Labianca, et al.. (2009). Off-Label Prescription of Antineoplastic Drugs: An Italian Prospective, Observational, Multicenter Survey. Tumori Journal. 95(6). 647–651. 15 indexed citations
15.
Tiseo, Marcello, Olga Martelli, Andrea Mancuso, et al.. (2007). Short Hydration Regimen and Nephrotoxicity of Intermediate to High-Dose Cisplatin-Based Chemotherapy for Outpatient Treatment in Lung Cancer and Mesothelioma. Tumori Journal. 93(2). 138–144. 65 indexed citations
16.
Gridelli, Cesare, Andrea Ardizzoni, Thierry Le Chevalier, et al.. (2004). Treatment of advanced non-small-cell lung cancer patients with ECOG performance status 2: results of an European Experts Panel. Annals of Oncology. 15(3). 419–426. 121 indexed citations
17.
Marinis, Filippo de, Maria Rita Migliorino, Luca Paoluzzi, et al.. (2003). Phase I/II trial of gemcitabine plus cisplatin and etoposide in patients with small-cell lung cancer. Lung Cancer. 39(3). 331–338. 10 indexed citations
18.
Marinis, Filippo de, Fabrizio Nelli, Maria Rita Migliorino, et al.. (2003). Gemcitabine, paclitaxel, and cisplatin as induction chemotherapy for patients with biopsy‐proven Stage IIIA(N2) nonsmall cell lung carcinoma. Cancer. 98(8). 1707–1715. 33 indexed citations
19.
Migliorino, M.R., Filippo de Marinis, Fabrizio Nelli, et al.. (2002). A 3-week schedule of gemcitabine plus cisplatin as induction chemotherapy for Stage III non-small cell lung cancer. Lung Cancer. 35(3). 319–327. 20 indexed citations
20.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Libor Havel Breakdown of academic impact, for papers by J Thiriaux Breakdown of academic impact, for papers by Naruo Yoshimura Breakdown of academic impact, for papers by Jessica Read Breakdown of academic impact, for papers by Maria Q. Baggstrom Breakdown of academic impact, for papers by Akihiro Nishiyama Breakdown of academic impact, for papers by C. Manegold Breakdown of academic impact, for papers by Jean-Louis Pujol Breakdown of academic impact, for papers by Jiichiro Sasaki Breakdown of academic impact, for papers by Gonçalo Forjaz
Rankless by CCL
2026